Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases
Authors:
- Cheryl F. LichtiCLCheryl F. Lichti
- Stacie BrattonSBStacie Bratton
- Neil C. MitchellNMNeil C. Mitchell
- Anna Gallus-ZawadaAGAnna Gallus-Zawada
- Vi-Huyen LeVLVi-Huyen Le
- Moshe FinelMFMoshe Finel
- Grover P. MillerGrover P. Miller
- Anna Radominska-PandyaARAnna Radominska-Pandya
- Jeffery H. MoranJMJeffery H. Moran
- 1 January 2008
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 324 (1) , 139-148
Abstract
Our understanding of human phase II metabolic pathways which facilitate detoxification and excretion of warfarin (Coumadin) is limited. The goal of this study was to test the hypothesis that there are specific human hepatic and extrahepatic UDP-glucuronosyltransferase (UGT) isozymes, which are responsible for conjugating warfarin and hydroxylated metabolites of warfarin. Glucuronidation activity of human liver microsomes (HLMs) and eight human recombinant UGTs toward (R)- and (S)-warfarin, racemic warfarin, and major cytochrome P450 metabolites of warfarin (4′-, 6-, 7-, 8-, and 10-hydroxywarfarin) has been assessed. HLMs, UGT1A1, 1A8, 1A9, and 1A10 showed glucuronidation activity toward 4′-, 6-, 7-, and/or 8-hydroxywarfarin with Km values ranging from 59 to 480 μM and Vmax values ranging from 0.03 to 0.78 μM/min/mg protein. Tandem mass spectrometry studies and structure comparisons suggested glucuronidation was occurring at the C4′-, C6-, C7-, and C8-positions. Of the hepatic UGT isozymes tested, UGT1A9 exclusively metabolized 8-hydroxywarfarin, whereas UGT1A1 metabolized 6-, 7-, and 8-hydroxywarfarin. Studies with extrahepatic UGT isoforms showed that UGT1A8 metabolized 7- and 8-hydroxywarfarin and that UGT1A10 glucuronidated 4′-, 6-, 7-, and 8-hydroxywarfarin. UGT1A4, 1A6, 1A7, and 2B7 did not have activity with any substrate, and none of the UGT isozymes evaluated catalyzed reactions with (R)- and (S)-warfarin, racemic warfarin, or 10-hydroxywarfarin. This is the first study identifying and characterizing specific human UGT isozymes, which glucuronidate major cytochrome P450 metabolites of warfarin with similar metabolic rates known to be associated with warfarin metabolism. Continued characterization of these pathways may enhance our ability to reduce life-threatening and costly complications associated with warfarin therapy.Keywords
This publication has 31 references indexed in Scilit:
- The Pharmocogenomics of Warfarin: Closing in on Personalized MedicineMolecular Interventions, 2006
- In silico pharmacogenetics of warfarin metabolismNature Biotechnology, 2006
- Engineering of a Recombinant Vitamin K-dependent γ-Carboxylation System with Enhanced γ-Carboxyglutamic Acid Forming CapacityJournal of Biological Chemistry, 2005
- The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†Drug Metabolism Reviews, 2001
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsChemical Research in Toxicology, 1992
- Clinical Pharmacokinetics and Pharmacodynamics of WarfarinClinical Pharmacokinetics, 1986
- Stereoselective metabolism of conformational analogs of warfarin by .beta.-naphthoflavone-inducible cytochrome P-450Journal of Medicinal Chemistry, 1985
- Interindividual Differences in the Response to Oral AnticoagulantsDrugs, 1977
- Protein binding of warfarin enantiomers in serum of humans and ratsJournal of Pharmacokinetics and Biopharmaceutics, 1977
- STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN*Journal of Clinical Investigation, 1963